Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(40.0%)
Phase 3
4(40.0%)
Phase 2
2(20.0%)
10Total
Phase 1(4)
Phase 3(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT01759849Completed

Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma

Role: collaborator

NCT00362349Phase 3Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Role: lead

NCT01632852Phase 1Completed

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Role: lead

NCT01499420Phase 2Completed

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Role: lead

NCT00680446Phase 3Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Role: lead

NCT00405184Phase 3Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Role: lead

NCT00391131Phase 3Completed

Subcutaneous Ig NextGen 16% in PID Patients

Role: lead

NCT01281774Phase 1Completed

A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

Role: lead

NCT01129661Phase 1Completed

Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

Role: lead

NCT00401739Phase 1Completed

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

Role: lead

NCT00225719Phase 2Completed

Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL

Role: lead

All 11 trials loaded